A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Triple-Negative and HER2+ Breast Cancer Patients

NANot yet recruitingINTERVENTIONAL
Enrollment

348

Participants

Timeline

Start Date

February 12, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Breast Cancers
Interventions
DEVICE

Hyperbaric oxygen treatment

Patients who meet the inclusion criteria will be enrolled and given hyperbaric oxygen intervention, with a minimum of 5 hyperbaric oxygen treatments per chemotherapy cycle, one per day for 60-90 minutes, for a total of 30-40 hyperbaric oxygen treatments (100% oxygen at a pressure of 2.0 ATA).

Trial Locations (1)

Unknown

Guangdong Provincial People's Hospital, Guangzhou

All Listed Sponsors
lead

Guangdong Provincial People's Hospital

OTHER